| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5271142
Max Phase: Preclinical
Molecular Formula: C18H16N6O2
Molecular Weight: 348.37
Associated Items:
Representations
Canonical SMILES: CCn1c(=O)c2ccnn2c2ccc(C(=O)NCc3cnccn3)cc21
Standard InChI: InChI=1S/C18H16N6O2/c1-2-23-16-9-12(17(25)21-11-13-10-19-7-8-20-13)3-4-14(16)24-15(18(23)26)5-6-22-24/h3-10H,2,11H2,1H3,(H,21,25)
Standard InChI Key: GFCBVBVJHRMUTB-UHFFFAOYSA-N
Associated Targets(Human)
PI3-kinase p110-alpha subunit 12269 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 348.37 | Molecular Weight (Monoisotopic): 348.1335 | AlogP: 1.39 | #Rotatable Bonds: 4 |
| Polar Surface Area: 94.18 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 0.39 | CX LogP: -0.24 | CX LogD: -0.24 |
| Aromatic Rings: 4 | Heavy Atoms: 26 | QED Weighted: 0.60 | Np Likeness Score: -1.95 |
References
| 1. Gu D, Zhang M, Cai L, Wang C, Zhou YB, Li J, Sheng R.. (2023) Discovery of 4-oxo-4,5-dihydropyrazolo[1,5-a]quinoxaline-7-carboxamide derivatives as PI3Kα inhibitors via virtual screening and docking-based structure optimization., 86 [PMID:37126967] [10.1016/j.bmc.2023.117288] |
Source
Source(1):